2025-12-29 - Analysis Report
Okay, here's a report analyzing Hims & Hers Health Inc. (HIMS) based on the provided data.

**1. Return Rate Comparison**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that provides personalized health and wellness solutions.
*   **HIMS Cumulative Return:** 121.51%
*   **VOO (S&P 500) Cumulative Return:** 77.16%
*   **Divergence:** 54.7 (Relative Divergence: 34.5)

**Analysis:**

HIMS has significantly outperformed the S&P 500 (VOO) with a cumulative return of 121.51% compared to VOO's 77.16%. The divergence of 54.7 indicates a considerable difference in performance. The relative divergence of 34.5 suggests the current divergence is in the lower half of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD  | Alpha   | Beta  | Cap(B) |
|------------|---------|------|---------|-------|--------|
| 2019-2021  | -42.0%  | 74.4% | -81.0%  | 0.0   | 1.5    |
| 2020-2022  | -19.0%  | 78.6% | -18.0%  | -0.0  | 1.5    |
| 2021-2023  | -65.0%  | 78.6% | -67.0%  | -0.1  | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0  | 5.5    |
| 2023-2025  | 126.0% | 80.8% | 58.0%  | 0.1   | 7.8    |

**Analysis:**

*   **CAGR:** The CAGR (Compound Annual Growth Rate) shows volatile performance. Negative CAGRs from 2019-2023, followed by strong positive CAGRs in the most recent periods.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha has significantly improved, indicating the potential to generate excess returns relative to the market.
*   **Beta:** The Beta is relatively low, suggesting that HIMS's price movements are less correlated with the overall market (S&P 500).
*   **Cap:** The market capitalization has been increasing, indicating company growth.

**2. Recent Stock Price Fluctuations**

*   **Close:** 34.31
*   **Last-market:** price: 34.31, previousClose: 34.67, change: -1.04
*   **5-day SMA:** 34.878
*   **20-day SMA:** 36.8975
*   **60-day SMA:** 43.0687

**Analysis:**

The stock price is currently below all three Simple Moving Averages (SMA), suggesting a short-term downtrend. The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, further confirming this trend. The most recent change of -1.04 suggests continued downward pressure.

**3. RSI, PPO, and Expected Return**

*   **Market Risk Indicator (MRI):** 1.0 (High Investment Recommended)
*   **RSI:** 23.10 (Oversold)
*   **PPO:** -0.1228
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -2.7 (short-term decline)
*   **Expected Return:** 31.3% (over 2 years, compared to S&P 500)

**Analysis:**

*   **MRI:** Despite the recent downturn, the Market Risk Indicator suggests a high investment opportunity.
*   **RSI:** The RSI value of 23.10 indicates the stock is oversold, potentially signaling a buying opportunity.
*   **PPO:** The negative PPO suggests a downtrend, but its low value might signal oversold conditions.
*   **Hybrid Signal:** The hybrid signal strongly recommends buying HIMS, suggesting long-term confidence.
*   **Recent Divergence Change:** Confirms the recent short-term decline.
*   **Expected Return:** The high expected return suggests significant upside potential if invested long-term.

**4. Recent News & Significant Events**

*   **Stock Fell 4% This Week:** Indicates recent negative price action.
*   **HIMS vs. TDOC Comparison:** Places HIMS in the context of its competitors in the telehealth market.
*   **$250 Million Share Repurchase Program:** This is generally a positive sign, as it indicates the company believes its stock is undervalued and is willing to invest in itself.
*   **Market's Panic is Irrational:** Suggests that the recent decline may be an overreaction and presents a buying opportunity.
*   **Carnegie Investment Counsel Acquires Shares:** Indicates institutional investment, which can be a positive sign.
*   **Valuation Reckoning Amid Sector Turbulence:** Highlights potential challenges in the sector that could impact HIMS's valuation.

**4-2) Analyst Opinions**

*   **Mean:** - (No rating provided)
*   **Opinions:** 12
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00

**Analysis:**

The average analyst target price of $44.67 represents a potential upside from the current price of $34.31.  However, the wide range between the high and low target prices ($85.00 and $25.00) suggests considerable uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

**Analysis:**

The data shows fluctuation in both EPS (Earnings Per Share) and revenue. Recent EPS shows a downward trend, while revenue has generally been increasing. The reoccurrence of the date '2025-11-03' is unusual and should be verified.

**6. Financial Information**

Revenue and Profitability:

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.60B  | 73.80%        |
| 2025-06-30   | $0.54B  | 76.39%        |
| 2025-03-31   | $0.59B  | 73.50%        |
| 2024-12-31   | $0.48B  | 76.81%        |
| 2024-09-30   | $0.40B  | 79.16%        |

Capital and Profitability:

| Quarter      | Equity | ROE     |
|--------------|--------|---------|
| 2025-09-30   | $0.58B | 2.72%   |
| 2025-06-30   | $0.56B | 7.55%   |
| 2025-03-31   | $0.55B | 9.01%   |
| 2024-12-31   | $0.48B | 5.46%   |
| 2024-09-30   | $0.44B | 17.18%  |

**Analysis:**

Revenue shows a generally increasing trend over the quarters, indicating growth. Profit margins are consistently high, suggesting a strong business model. However, ROE (Return on Equity) has been volatile and generally decreasing, indicating potential concerns about how efficiently the company is using its equity to generate profits.

**7. Comprehensive Analysis (Summary)**

HIMS has significantly outperformed the S&P 500, but recent performance has been weak. The stock is currently in a short-term downtrend and is considered oversold by some indicators.  Analyst target prices suggest potential upside, but there's considerable disagreement on the magnitude.  News events are mixed, with positive developments like a share repurchase program offset by valuation concerns and sector turbulence. Revenue is growing and profit margins are high, but ROE has been declining, and recent EPS is trending downward.

**Overall Recommendation:**

Based on the provided data, HIMS presents a mixed picture. While the long-term outlook is promising, the short-term indicators suggest caution. The stock appears oversold, and analyst target prices suggest potential upside. However, the recent downtrend, declining ROE, and mixed news flow warrant careful consideration. An investment in HIMS should be considered high-risk, high-reward. Further research into the reasons behind the declining ROE and EPS would be prudent before making an investment decision. It is also important to verify the accuracy of the provided quarterly data.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.